P3 Health Partners Q4 2022 net loss $532.3M on $463.5M goodwill impairment; revenue up 40%

P3 Health Partners Inc.

2023-Q1 EPS reported -$0.22 revenue$302,077,000

Q4 capitated revenue $254.0M (+40% YoY); net loss $532.3M vs $118.2M loss, primarily due to $463.5M goodwill impairment.
Adjusted EBITDA loss $40.1M vs $35.6M; Adjusted EBITDA PMPM loss improved to $133 from $177 in Q4 2021.
Full-year 2022 network contribution improved 65% vs 2021; company affirms 2023 guidance, expects Adjusted EBITDA positive in early 2024.
Introduced year-end medical margin guidance as new non-GAAP metric.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

P3 Health Partners Inc. updated its the fourth quarter and full year ended December 31, 2022 guidance (reaffirmed).

Period: the fourth quarter and full year ended December 31, 2022
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On March 31, 2023, P3 Health Partners Inc. (the “Company” or “P3”) announced its financial results for the three months and full year ended December 31, 2022.

View on SEC.gov

13 earnings releases filed in the last 30 days. Browse all earnings releases →

P3 Health Partners Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-039608

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.